Last updated on September 2018

Study Of Nivolumab Alone Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma


Brief description of study

This study is a multicentric phase II open-label trial consisting of 6 cycles Nivolumab (2 weeks interval) followed by a PET-CT scan. The treatment will be allocated according to PET and CT scan responses. :

  • In case of CMR according to Lugano Classification (Cheson et al.2014, PET-CT based response), patients will receive 18 additional cycles of Nivolumab, according to CT-based response at Cycle 12.
  • In case of Partial Metabolic Response (PMR) or No Metabolic Response(NMR), according to Lugano Classification (Cheson et al.2014, PET-CT based response) patients will receive 12 to 18 cycles of Nivolumab combined with Vinblastin according to CT-based response at Cycle 12.
  • In case of progressive disease, according to Lugano Classification (Cheson et al.2014, PET-CT scan based response) patients will be considered in treatment failure.

Clinical Study Identifier: NCT03580408

Contact Investigators or Research Sites near you

Start Over

ZNA Stuivenberg

Antwerpen, Belgium
  Connect »

Az Sint Jan

Bruges, Belgium
  Connect »

Hopital Jolimont

Haine saint paul, Belgium
  Connect »

Az Groeninge

Kortrijk, Belgium
  Connect »

CHU de Clermont Ferrand

Clermont Ferrand, France
  Connect »

CHD de Vend e

La Roche-sur-Yon, France
  Connect »

CH La Rochelle

La Rochelle, France
  Connect »

CH du Mans

Le Mans, France
  Connect »

Centre Leon Berard

Lyon Cedex 8, France
  Connect »

Ch Rene Dubos

Pontoise, France
  Connect »

CH de Saint Brieuc

Saint-Brieuc, France
  Connect »

IUCT Toulouse

Toulouse, France
  Connect »

CHU Brabois

Vandoeuvre les Nancy, France
  Connect »

Institut Gustave Roussy

VILLEJUIF Cedex, France
  Connect »

CHU Lyon Sud

Pierre-Bénite, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.